183 related articles for article (PubMed ID: 36150668)
1. Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis.
G S Saad C; S R Silva M; Sampaio-Barros PD; C B Moraes J; G Schainberg C; Gonçalves CR; Shimabuco AY; Aikawa NE; F N Yuki E; G Pasoto S; V K Kupa L; K Aoyama R; S R Araujo C; Silva CA; Medeiros-Ribeiro AC; Bonfa E
Joint Bone Spine; 2023 Jan; 90(1):105464. PubMed ID: 36150668
[TBL] [Abstract][Full Text] [Related]
2. Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis.
Medeiros-Ribeiro AC; Bonfiglioli KR; Domiciano DS; Shimabuco AY; da Silva HC; Saad CGS; Yuki EFN; Pasoto SG; Araujo CSR; Nakai TL; Silva CA; Pedrosa T; Kupa LVK; Silva MSR; Balbi GGM; Kallas EG; Aikawa NE; Bonfa E
Ann Rheum Dis; 2022 May; 81(5):710-719. PubMed ID: 35135832
[TBL] [Abstract][Full Text] [Related]
3. Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose.
Pereira RMR; Dagostin MA; Caparbo VF; Sales LP; Pasoto SG; Silva CA; Yuki EFN; Saad CGS; Medeiros-Ribeiro AC; Kupa LVK; Fusco SRG; Martins VAO; Martins CCMF; Barbas CV; Shinjo SK; Aikawa NE; Bonfa E
Clinics (Sao Paulo); 2023; 78():100150. PubMed ID: 36529052
[TBL] [Abstract][Full Text] [Related]
4. Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial.
Araujo CSR; Medeiros-Ribeiro AC; Saad CGS; Bonfiglioli KR; Domiciano DS; Shimabuco AY; Silva MSR; Yuki EFN; Pasoto SG; Pedrosa T; Kupa LVK; Zou G; Pereira RMR; Silva CA; Aikawa NE; Bonfa E
Ann Rheum Dis; 2022 Jun; 81(6):889-897. PubMed ID: 35193873
[TBL] [Abstract][Full Text] [Related]
5. Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases.
Aikawa NE; Kupa LVK; Medeiros-Ribeiro AC; Saad CGS; Yuki EFN; Pasoto SG; Rojo PT; Pereira RMR; Shinjo SK; Sampaio-Barros PD; Andrade DCO; Halpern ASR; Fuller R; Souza FHC; Guedes LKN; Assad APL; Moraes JCB; Lopes MRU; Martins VAO; Betancourt L; Ribeiro CT; Sales LP; Bertoglio IM; Bonoldi VLN; Mello RLP; Balbi GGM; Sartori AMC; Antonangelo L; Silva CA; Bonfa E
Ann Rheum Dis; 2022 Jul; 81(7):1036-1043. PubMed ID: 35277389
[TBL] [Abstract][Full Text] [Related]
6. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
Flouri ID; Markatseli TE; Boki KA; Papadopoulos I; Skopouli FN; Voulgari PV; Settas L; Zisopoulos D; Iliopoulos A; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
J Rheumatol; 2018 Jun; 45(6):785-794. PubMed ID: 29606666
[TBL] [Abstract][Full Text] [Related]
7. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis.
Nissen M; Delcoigne B; Di Giuseppe D; Jacobsson L; Hetland ML; Ciurea A; Nekvindova L; Iannone F; Akkoc N; Sokka-Isler T; Fagerli KM; Santos MJ; Codreanu C; Pombo-Suarez M; Rotar Z; Gudbjornsson B; van der Horst-Bruinsma I; Loft AG; Möller B; Mann H; Conti F; Yildirim Cetin G; Relas H; Michelsen B; Avila Ribeiro P; Ionescu R; Sanchez-Piedra C; Tomsic M; Geirsson ÁJ; Askling J; Glintborg B; Lindström U
Rheumatology (Oxford); 2022 Nov; 61(12):4741-4751. PubMed ID: 35323903
[TBL] [Abstract][Full Text] [Related]
8. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2.
Shinjo SK; de Souza FHC; Borges IBP; Dos Santos AM; Miossi R; Misse RG; Medeiros-Ribeiro AC; Saad CGS; Yuki EFN; Pasoto SG; Kupa LVK; Ceneviva C; Seraphim JC; Pedrosa TN; Vendramini MBG; Silva CA; Aikawa NE; Bonfá E
Rheumatology (Oxford); 2022 Aug; 61(8):3351-3361. PubMed ID: 34664616
[TBL] [Abstract][Full Text] [Related]
9. Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
George MD; Baker JF; Ogdie A
J Rheumatol; 2020 Jun; 47(6):826-834. PubMed ID: 31474599
[TBL] [Abstract][Full Text] [Related]
10. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
[TBL] [Abstract][Full Text] [Related]
11. Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study.
Fagerli KM; van der Heijde D; Heiberg MS; Wierød A; Kalstad S; Rødevand E; Mikkelsen K; Kvien TK; Lie E
Rheumatology (Oxford); 2014 Jun; 53(6):1087-94. PubMed ID: 24501243
[TBL] [Abstract][Full Text] [Related]
12. Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus.
Yuki EFN; Borba EF; Pasoto SG; Seguro LP; Lopes M; Saad CGS; Medeiros-Ribeiro AC; Silva CA; de Andrade DCO; Kupa LVK; Betancourt L; Bertoglio I; Valim J; Hoff C; Formiga FFC; Pedrosa T; Kallas EG; Aikawa NE; Bonfa E
Arthritis Care Res (Hoboken); 2022 Apr; 74(4):562-571. PubMed ID: 34806342
[TBL] [Abstract][Full Text] [Related]
13. Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination.
Andreica I; Blazquez-Navarro A; Sokolar J; Anft M; Kiltz U; Pfaender S; Vidal Blanco E; Westhoff T; Babel N; Stervbo U; Baraliakos X
RMD Open; 2022 Sep; 8(2):. PubMed ID: 36104115
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial.
Medeiros-Ribeiro AC; Aikawa NE; Saad CGS; Yuki EFN; Pedrosa T; Fusco SRG; Rojo PT; Pereira RMR; Shinjo SK; Andrade DCO; Sampaio-Barros PD; Ribeiro CT; Deveza GBH; Martins VAO; Silva CA; Lopes MH; Duarte AJS; Antonangelo L; Sabino EC; Kallas EG; Pasoto SG; Bonfa E
Nat Med; 2021 Oct; 27(10):1744-1751. PubMed ID: 34331051
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors.
Venerito V; Stefanizzi P; Fornaro M; Cacciapaglia F; Tafuri S; Perniola S; Iannone F; Lopalco G
RMD Open; 2022 Jan; 8(1):. PubMed ID: 34987092
[TBL] [Abstract][Full Text] [Related]
16. Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study.
Michielsens CAJ; den Broeder N; Mulder MLM; van den Hoogen FHJ; Verhoef LM; den Broeder AA
Rheumatology (Oxford); 2022 May; 61(6):2307-2315. PubMed ID: 34599803
[TBL] [Abstract][Full Text] [Related]
17. Anti-SARS-CoV-2 antibody decay after vaccination and immunogenicity of the booster dose of the BNT162b2 mRNA vaccine in patients with psoriatic arthritis on TNF inhibitors.
Venerito V; Stefanizzi P; Martinelli A; Fornaro M; Galeone MG; Tafuri S; Iannone F; Lopalco G
Clin Exp Rheumatol; 2023 Jan; 41(1):166-169. PubMed ID: 36441661
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy.
Sampaio-Barros PD; Medeiros-Ribeiro AC; Luppino-Assad AP; Miossi R; da Silva HC; Yuki EFVN; Pasoto SG; Saad CGS; Silva CA; Kupa LVK; Deveza GBH; Pedrosa TN; Aikawa NE; Bonfá E
Rheumatology (Oxford); 2022 Jun; 61(SI2):SI169-SI174. PubMed ID: 34894235
[TBL] [Abstract][Full Text] [Related]
19. Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity.
Pasoto SG; Halpern ASR; Guedes LKN; Ribeiro ACM; Yuki ENF; Saad CGS; da Silva CAA; de Vinci Kanda Kupa L; Villamarín LEB; de Oliveira Martins VA; Martins CCMF; Deveza GBH; Leon EP; Bueno C; Pedrosa TN; Santos REB; Soares R; Aikawa NE; Bonfa E
Clin Rheumatol; 2022 Jul; 41(7):2079-2089. PubMed ID: 35306594
[TBL] [Abstract][Full Text] [Related]
20. Strong response after fourth dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine.
Aikawa NE; Kupa LVK; Silva CA; Saad CGS; Pasoto SG; Yuki EFN; Fusco SRG; Shinjo SK; Andrade DCO; Sampaio-Barros PD; Pereira RMR; Chasin ACS; Shimabuco AY; Luppino-Assad AP; Leon EP; Lopes MH; Antonangelo L; Medeiros-Ribeiro AC; Bonfa E
Rheumatology (Oxford); 2022 Dec; 62(1):480-485. PubMed ID: 35639644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
